Flagship Ventures Fund IV-Rx, L.P.'s Net Worth
$4.78 Billion
Who is Flagship Ventures Fund IV-Rx, L.P.?
Flagship Ventures Fund IV-Rx, L.P. has an estimated net worth of $4.78 Billion. This is based on reported shares across multiple companies, which include Moderna, Inc., Seres Therapeutics, Inc., Editas Medicine, Inc., Rubius Therapeutics, Inc., Syros Pharmaceuticals, Inc., Eleven Biotherapeutics, Inc., Axcella Health Inc., and Evelo Biosciences, Inc..
SEC CIK
Flagship Ventures Fund IV-Rx, L.P.'s CIK is 0001590973
Past Insider Trading and Trends
2018 was Flagship Ventures Fund IV-Rx, L.P.'s most active year for acquiring shares with 20 total transactions. Flagship Ventures Fund IV-Rx, L.P.'s most active month to acquire stocks was the month of April. 2016 was Flagship Ventures Fund IV-Rx, L.P.'s most active year for disposing of shares, totalling 47 transactions. Flagship Ventures Fund IV-Rx, L.P.'s most active month to dispose stocks was the month of April. 2022 saw Flagship Ventures Fund IV-Rx, L.P. paying a total of $52,069,996.75 for 33,716,630 shares, this is the most they've acquired in one year. In 2020 Flagship Ventures Fund IV-Rx, L.P. cashed out on 32,241,407 shares for a total of $68,219,276.30, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Moderna, Inc. (MRNA) Snapshot price: $100.17
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -36.29% | -11.05M |
—
|
—
| 19.41M |
Aug 17
| |||
Form 4
| -1.71% | -1.00M |
$68.22 | -$68,219,276.30 | 57.31M |
May 21 - May 22
| |||
Form 4
| -29.46% | -12.28M |
—
|
—
| 29.41M |
May 11
| |||
Form 4
| -5.75% | -9.67M |
$18.87 | -$8,196,935.61 | 158.57M |
Dec 9 - Dec 11
| |||
Form 4
|
∞
| 47.34M |
—
|
—
| 47.34M |
Dec 11
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Seres Therapeutics, Inc. (MCRB) Snapshot price: $1.035
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -39.84% | -7.91M |
—
|
—
| 11.94M |
Nov 23
| |||
Form 4
| -12.02% | -2.00M |
$27.60 | -$27,600,000.00 | 14.64M |
May 25
| |||
Form 4
|
∞
| 11.63M |
—
|
—
| 11.63M |
Jun 25 - Jun 26
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Editas Medicine, Inc. (EDIT) Snapshot price: $7.155
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -30.97% | -1.55M |
—
|
—
| 3.46M |
Aug 11
| |||
Form 4
|
∞
| 4.96M |
—
|
—
| 4.96M |
Feb 8
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Rubius Therapeutics, Inc. (RUBY) Snapshot price: $0.057
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +185.29% | 33.3M |
—
|
—
| 51.27M |
Jul 20
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Syros Pharmaceuticals, Inc. (SYRS) Snapshot price: $7.14
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -35.64% | -1.66M |
—
|
—
| 2.99M |
Aug 17
| |||
Form 4
| +47.55% | 4.59M |
$12.50 | $5,000,000.00 | 14.25M |
Jul 6
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||